Preview

FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology

Advanced search

Search


Order results by:     
 
Issue Title
 
Vol 8, No 4 (2015) THE COST OF NUTRITION ALTERNATIVES FOR PREMATURE INFANTS IN RUSSIA Abstract  similar documents
K. V. Gerasimova, M. V. Avxentyeva, I. A. Belyaeva
"... breastfeeding. Methods. The cost of providing 100 ml of breast milk (BM) using clinical breast pump and 100 ml ..."
 
Vol 11, No 2 (2018) Economic evaluation of postoperative hypofractionated radiation therapy in patients with breast cancer Abstract  similar documents
G. V. Afonin, Yu. A. Ragulin, M. V. Avxentyeva, I. A. Gulidov, S. A. Ivanov, A. D. Kaprin
"... the treatment costs in patients with breast cancer while maintaining a high treatment efficacy and quality ..."
 
Vol 6, No 3 (2013) PHARMACOECONOMIC ANALYSIS OF DOCETAXEL IN THE ADJUVANT THERAPY OF BREAST CANCER Abstract  similar documents
R. I. Yagudina, I. Yu. Zinchuk
"... it was determined that for 10-years horizon cost rate for the treatment of one patient with breast cancer will be 1 ..."
 
Vol 9, No 1 (2016) COST-EFFECTIVENESS ANALYSIS OF BRENTUXIMAB VEDOTIN IN ADULTS WITH RELAPSED OR REFRACTORY HODGKIN’S LYMPHOMA Abstract  similar documents
G. R. Khachatryan, D. V. Fedyaev, M. V. Avxentyeva, V. S. Dombrovskiy
"... is an appropriate alternative as ICER per LY is lower than for standard treatment Ch ± RT + alloSCT vs Ch ± RT. Cost ..."
 
Vol 9, No 3 (2016) DRUGS PROVIDED TO BREAST CANCER PATIENTS WITHIN THE STATE PROGRAMS OF DRUG SUPPLY Abstract  similar documents
M. V. Avxentyeva, V. I. Bogin, E. V. Derkach, V. V. Omelyanovskiy, M. B. Stenina, A. V. Tarakanov, M. Yu. Frolov
"... The purpose of our research was to analyze the actual practice of medicine in patients with breast ..."
 
Vol 5, No 1 (2012) COST OF ILLNESS ANALYSIS: TYPES, METHODOLOGY, RUSSIAN SPECIFICS Abstract  similar documents
R. I. Yagudina, I. Yu. Zinchuk, M. M. Litvinenko
"... Cost of illness is one of the basic methods of pharmacoeconomical estimation and in substance ..."
 
Vol 7, No 3 (2014) THE ANALYSIS OF METHODOLOGIC CHARACTERISTICS OF RESEARCHES ON SOCIAL AND ECONOMIC BURDEN OF DISEASES IN RUSSIA IN THE FRAMES OF DEVELOPMENT OF STANDARD COST OF ILLNESS METHODOLOGY FOR THE HEALTH TECHNOLOGY ASSESSMENT Abstract  similar documents
V. I. Ignatyeva, M. V. Avxentyeva
"... there are no uninamioulsly accepted methods and approaches for this type of research. The cost of illness method (assessment ..."
 
Vol 9, No 2 (2016) METASTATIC COLORECTAL TREATMENT COSTS OF USING TARGETED DRUGS IN SECOND AND FURTHER LINES THERAPY Abstract  similar documents
N. A. Avxentyev, E. V. Derkach, E. A. Pyadushkina, M. D. Ter-Ovanesov
"... per patient medication costs of using regorafenib are 255,000 rubles, which is 104,000 rubles less ..."
 
Vol 9, No 4 (2016) THE COSTS OF REGIONAL ANESTHESIA WITH THE USE OF LEVOBUPIVACAINE, RACEMIC BUPIVACAINE AND ROPIVACAINE Abstract  similar documents
G. E. Ulrikh, A. V. Rudakova
"... levobupivacaine allows you to reduce costs 29.6-56.9 per cent compared with bupivacaine and ropivacaine. Taking ..."
 
Vol 11, No 1 (2018) Pharmacoeconomic assessment of antipsychotic treatment in outpatients with schizophrenia Abstract  similar documents
I. A. Vilyum, B. V. Andreev, M. A. Proskurin, Yu. E. Balykina
"... to the reproduced AA (up to 100% replacement of reference  medications), the costs would remain to be higher than ..."
 
Vol 11, No 2 (2018) Pharmacoeconomic analysis of using typical and atypical antipsychotics in schizophrenia Abstract  similar documents
I. A. Vilyum, B. V. Andreev, M. A. Proskurin, Yu. E. Balykina
"... . For the «number of hospitalization-free days per year», the use of AA was more cost-effective only versus the 100 ..."
 
Vol 8, No 2 (2015) REVIEW OF THE INTERNATIONAL PRACTICE OF COST-SHARING MECHANISM IN NATIONAL HEALTH CARE SYSTEMS Abstract  similar documents
Natalia Nikolayevna Sisigina, Vitalii Vladimirovich Omel'yanovskii, Nikolay Alexandrovich Avxentyev
"... The article gives a review of international experience of using of cost-sharing mechanism ..."
 
Vol 10, No 3 (2017) Evaluation of economic damage from multiple sclerosis in the city of Ufa, Russia Abstract  similar documents
E. V. Ivanova, K. Z. Bachtiyarova
"... and premature mortality (indirect costs). Results. Because of MS only in the city Ufa, the Russian economy loses ..."
 
Vol 7, No 1 (2014) ECONOMIC ASSESSMENT OF MAGNESIUM DEFICIENCY CORRECTION FOR BASIC THERAPY EFFICACY OF UNCONTROLLED ASTHMA IN CHILDREN Abstract  similar documents
V. I. Petrov, I. N. Shishimorov, O. V. Magnitskaya, Ju. V. Ponomareva
"... the cost of achieving control and cost per symptom-free day after 12 and 24 weeks of therapy. ..."
 
Vol 10, No 4 (2017) PHARMACOECONOMIC JUSTIFICATION OF A WIDER USE OF PREVENTIVE HEMOPHILIA THERAPY IN THE RUSSIAN FEDERATION Abstract  similar documents
M. Yu. Frolov, V. A. Rogov
"... and 2 do not exceed one GDP per capita, and the technologies are cost-effective. Conclusion. In both ..."
 
Vol 7, No 3 (2014) ASSESSMENT OF NECESSARY FINANCIAL EXPENSES ON THE DRUG SUPPLY OF THE PATIENTS WITH ORPHAN DISEASES IN THE RUSSIAN FEDERATION Abstract  similar documents
M. V. Sura, K. V. Gerasimova, V. V. Omelyanovskiy, M. V. Avksentyeva
"... per year: average-weighted costs per one child with Mucopolysaccharidoses type VI amounted to 40 ..."
 
Vol 11, No 4 (2018) International experience in determining the cost-effectiveness thresholds Abstract  similar documents
T. P. Bezdenezhnykh, N. Z. Musina, V. K. Fedyaeva, T. S. Tepcova, V. A. Lemeshko, V. V. Omelyanovsky
"... the presence of HTA systems. The CeT is expressed as additional cost per unit of incremental health benefit ..."
 
Vol 9, No 1 (2016) COMPARATIVE CLINICAL AND ECONOMIC ANALYSIS OF THE INTENSIFICATION THERAPY IN PATIENTS WITH UNCONTROLLED DIABETES TYPE 2 USING BASAL INSULIN OR DAPAGLIFLOZIN Abstract  similar documents
V. I. Petrov, S. V. Nedogoda, M. Yu. Frolov, A. S. Salasyuk, I. N. Barykina, V. O. Smirnova, V. Yu. Khripaeva
"... according to standard pharmacoeconomic methods: cost-utility analysis (CUA), budget impact analysis (BIA ..."
 
Vol 5, No 2 (2012) THE ANALYSIS OF COST OF ILLNESS OF PREGNANT WOMEN WITH SYPHILIS Abstract  similar documents
A. I. Ovod, M. D. Mukovnina
"... . 110,8 на 100 тыс. пациенток, у которых беременность заверши- лась родами [11]. За период с 1991 по ..."
 
Vol 7, No 1 (2014) ABC END VEN ANALYSYS OF COSTS FOR MEDICINE SAND MEDICAL TREATMENT COSTS PATIENT Abstract  similar documents
M. A. Shapovalova, L. R. Koretskaya
"... of pharmacotherapy and medical services in the department of neurology. An assessment of the costs of hospitalization ..."
 
Vol 9, No 1 (2016) PHARMACOECONOMIC STUDY OF LENVIMA (LENVATINIB) IN ADVANCED PROGRESSIVE RADIO IODINE REFRACTORY DIFFERENTIATED THYROID CANCER IN THE RUSSIAN FEDERATION Abstract  similar documents
M. Yu. Frolov, V. A. Rogov
"... providing in the proposed model, 1628 additional years of life for patients per 5 years. Additional costs ..."
 
Vol 7, No 3 (2014) MODELI NG CLINICAL AND ECONOMIC OUTCOMES OF TESTING FOR LTBI WITH T-SPOT.TB IN IMMUNOCOMPROMISED CHILDREN Abstract  similar documents
V. I. Ignatyeva, M. V. Avxentyeva, V. V. Omelyanovsky, G. R. Khachatryan
"... was possible in 2 cases. The total costs per cohort were 1.71 mln RUR. in case of TST testing (including ..."
 
Vol 7, No 1 (2014) PATIENTS WITH NEUROLOGICAL DISEASES: RATIONALE FOR PHARMACOECONOMIC EVALUATION OF COST OPTIMIZATION FOR MANAGEMENT WITH NEURON-SPECIFIC PROTEINS ASSESSMENT AS MARKERS OF INCREASED BLOOD-BRAIN-BARRIER PERMEABILITY Abstract  similar documents
D. V. Blinov
"... system by this method were determined. It could be an example of a direct impact on the cost of treatment ..."
 
Vol 6, No 3 (2013) COST-UTILITY ANALYSIS OVER USE OF TYROSINE KINASE INHIBITORS (TASIGNA AND GLEEVEC) FOR TREATMENT OF CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE AS FIRST-LINE THERAPY FOR DE NOVO PATIENTS Abstract  similar documents
R. I. Yagudina, A. Yu. Kulikov, I. A. Komarov
"... incidence is about 1-2 cases on 100 000 men annually. Pharmacoeconomic evaluation of this pathology ..."
 
Vol 8, No 2 (2015) ASSESSMENT OF ECONOMIC EFFICIENCY OF APPLICATION OF RALTEGRAVIR BY PATIENTS WITHOUT EXPERIENCE OF TYPE 1 HIV INFECTION THERAPY IN RUSSIA Abstract  similar documents
Elamin H. Elbasha, Elena Aleksandrovna Pyadushkina, Maria Vladimirovna Avxentyeva, Alexander Gennadievich Tolkushin, Maxim Yurievich Frolov
"... The purpose of the work performed was assessment of cost efficiency of Raltegravir within ..."
 
Vol 7, No 2 (2014) THE ANALYSIS OF THE LIPETSK PHARMACEUTICAL MARKET OF NASAL GLUCOCORTICOSTEROID Abstract  similar documents
K. V. Danilova, I. M. Razdorskaya
"... . lane. from English. 2nd ed [Marketing menedzhment: analiz, planirovanie, vnedrenie, kontrol'. per. s ..."
 
Vol 6, No 4 (2013) Pharmacoeconomic analysis of fluid therapy in the treatment of patients with peritonitis Abstract  similar documents
R. I. Yagudina, M. M. Murashko
"... and Sterofundin drugs were compared during the analysis. A cost analysis, cost-effectiveness analysis, budget ..."
 
Vol 8, No 4 (2015) CLINICAL AND ECONOMIC EVALUATION OF THROMBOPOIETIN RECEPTOR AGONISTS IN THE TREATMENT OF CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA IN ADULTS Abstract  similar documents
E. A. Pyadushkina, M. Yu. Frolov, M. V. Avksentyeva
"... for the cost-minimization analysis (model 1) and analysis of the budget impact TRA usage (model 2 ..."
 
Vol 7, No 2 (2014) EPIDEMIOLOGIC RESEARCH ON EPILEPSY IN MINSK Abstract  similar documents
T. V. Dokukina, T. S. Golubeva, I. V. Matveichuk, M. V. Mahrov, V. M. Loseva, E. V. Krupenkina, S. A. Marchuk
"... .2 per 100,000 population in 2008 to 275.5 per 100,000 population in 2012, while the incidence rate ..."
 
Vol 5, No 3 (2012) CLINICAL AND ECONOMIC BENEFITS OF HUMAN INSULIN ANALOGUESUSE Abstract  similar documents
E. E. Arinina, M. A. Rashyd
"... ®) were 21774 rubles per patient/year, while the cost of an averted severe hypoglycemia was 24728 rubles ..."
 
Vol 8, No 4 (2015) PHARMACOECONOMIC EVALUATION OF INFLUENZA AND PNEUMOCOCCAL VACCINATION IN EMPLOYEES OF THE JOINT STOCK COMPANY "RUSSIAN RAILWAYS" (JSCO "RZD") ON INVESTMENT FOR THE EMPLOYER Abstract  similar documents
D. A. Zhukov
"... statistical software was not used). The author presented the method of direct and indirect costs calculation ..."
 
Vol 9, No 3 (2016) METHOD «COST-EFFECTIVENESS» IN EVALUETION OF ATIBIOTIC TREATMENT OF ACYTR OBSTRUCTIVE BRONCHITIS IN CHILDREN IN HOSPITAL Abstract  similar documents
O. V. Zhukova, S. V. Kononova
"... included 2259 patient’s data files. The age of patients ranged from 0 to 18 years old. «Cost-effectiveness ..."
 
Vol 5, No 3 (2012) COST-UTILITY ANALYSIS PATIENTS WITH LOW BACK PAIN AFTER TREATMENT INTRAOSSEOUS BLOCKADES Abstract  similar documents
M. V. Yakovlev, A. U. Kulikov, E. L. Sokov, I. E. Kornilova
"... , myorelaxants, physical therapy). Measured direct costs at 1-year follow-up. Quality of life was measured ..."
 
Vol 9, No 2 (2016) PHARMACOECONOMIC ANALYSIS OF THE THERAPY OF СHRONIC OBSTRUCTIVE PULMONARY DISEASE PATIENTS IN HOSPITAL CONDITIONS Abstract  similar documents
E. E. Vidyakina, S. V. Malchikova
"... records of the patient, the analysis of cost of illness, ABC VEN — analysis. Results. The results of АВС ..."
 
Vol 8, No 4 (2015) PLANNING OF EXTENT AND FINANCIAL EXPENSES FOR DELIVERY OF HEALTH CARE IN HOSPITALS AT THE FEDERAL AND REGIONAL LEVELS Abstract  similar documents
M. V. Sura
"... expenses per extent unit), established by PSG and TPSG for 2015. The above regional norms have been ..."
 
Vol 5, No 2 (2012) METHODOLOGY OF COST-UTILITY ANALYSIS IN PHARMACOECONOMICSTUDIES Abstract  similar documents
R. I. Yagudina, I. V. Sorokovikov
"... pharmacoeconomic cost-utility analysis – CUA is at third place by popularity (10% of studies ..."
 
Vol 11, No 3 (2018) Determination of a willingness-to-pay threshold and decision-making in financing the healthcare technologies Abstract  similar documents
T. S. Teptsova, T. P. Bezdenezhnyh, V. K. Fedyaeva, N. Z Musina, G. R. Hachatryan, V. V. Tarasov
"... is an empirical assessment of the cost-effectiveness threshold that reflects the utmost productivity of the health ..."
 
Vol 5, No 3 (2012) PHARMACOECONOMIC EVALUATION OF THE MEDICINAL PRODUCTS ERLOTINIB, DOCETAXEL, PEMETREXED AND GEFITINIB IN THE SECOND-LINE TREATMENT OF LOCALLY-ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER Abstract  similar documents
A. U. Kulikov
"... , где CER – показатель «затраты – эффективность»; Cost – затраты на медицинскую технологию, руб.; Ef ..."
 
Vol 11, No 2 (2018) Clinical and economic efficiency of the loop ileostomy closure by various methods Abstract  similar documents
A. V. Veselov, S. I. Achkasov, O. I. Sushkov, A. I. Moskalev, I. S. Lantsov
"... for the anastomosis formation. Results. The average cost of the treatments (per patient) in groups 1 and 2 was 131 ..."
 
Vol 8, No 1 (2015) SOCIAL AND ECONOMIC BURDEN OF FIVE NATURAL FOCAL INFECTIONS IN THE RUSSIAN FEDERATION Abstract  similar documents
A. E. Platonov, N. A. Avksentyev, M. V. Avksentyeva, E. V. Derkach, O. V. Platonova, A. V. Titkov, N. M. Kolyasnikova
"... Study objective: to perform assessment of the social and economic burden (analysis of the cost ..."
 
Vol 6, No 4 (2013) Pharmacoeconomical assessment of сerebrolysin in the treatment of the acute disturbances of cerebral circulation Abstract  similar documents
A. Yu. Kulikov, L. A. Komarov
"... of approaches to treatment policy of this group of patients. We performed cost-effectiveness analysis ..."
 
Vol 11, No 3 (2018) Pharmacoeconomic analysis of using belimumab for the treatment of systemic lupus erythematosus Abstract  similar documents
A. G. Tolkushin, N. L. Pogudina
"... rubles vs 2.88 million rubles were indirect medical costs) on average per patient in the belimumab group ..."
 
Vol 9, No 4 (2016) FACTORS AND EFFECTS OF PRIVATE HEALTH SPENDING Abstract  similar documents
O. A. Zarubina, N. N. Sisigina
"... health expenditure, regulatory measures on cost sharing, paid medical services, voluntary health ..."
 
Vol 7, No 2 (2014) THE ANALYSIS OF THE EFFECTIVENESS OF THROMBOPROPHYLAXIS AMONG PREGNANT WOMEN WITH MESENCHYMAL DYSPLASIA Abstract  similar documents
E. G. Kudinova, A. P. Momot, N. V. Trukhacheva
"... and accordingly the economic costs of medical care. ..."
 
Vol 6, No 2 (2013) COST-EFFECTIVENESS ANALYSIS OVER USE OF TYROSINE KINASE INHIBITORS (TASIGNA AND GLEEVEC) FOR TREATMENT OF CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE AS FIRST-LINE THERAPY FOR DE NOVO PATIENTS Abstract  similar documents
R. I. Yagudina, A. Yu. Kulikov, I. A. Komarov
"... performed cost-effectiveness analysis on the basis of two tyrosine kinase inhibitors in Russian Federation ..."
 
Vol 6, No 2 (2013) FIRST RUSSIAN TYPE 2 DIABETES MELLITUS SIMULATION MODEL WITH DISCREET EVENTS MODELING. HEALTH-ECONOMIC ANALYSIS Abstract  similar documents
A. S. Kolbin, O. K. Khmelnitskiy, A. A. Kurylev, Yu. E. Balykina, M. A. Proskurin, E. P. Kolpak, M. V. Bure
"... .). Cost-effectiveness analysis was performed. Results: The developed model allows to assess the risk ..."
 
Vol 8, No 4 (2015) ABC-, VEN и частотный анализ терапии фибрилляции предсердий в условиях «типичной практики» Abstract  similar documents
 
1 - 50 of 170 Items 1 2 3 4 > >> 

Search tips:

  • Search terms are case-insensitive
  • Common words are ignored
  • By default articles containing any term in the query are returned (i.e., OR is implied)
  • Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
  • Combine multiple words with AND to find articles containing all terms; e.g., education AND research
  • Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
  • Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
  • Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)